Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ultragenyx Pharmaceutical... (RARE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

40.11

-3.05 (-7.07%)

At close: Jan 14, 2025, 3:59 PM

39.10

-2.52%

Pre-market Jan 15, 2025, 04:18 AM EST

undefined% (undefined)

Bid	38.12
Market Cap	3.70B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-6.35
PE Ratio (ttm)	-6.32
Forward PE	n/a
Analyst	Buy

Ask	46.12
Volume	788,455
Avg. Volume (20D)	842,022
Open	44.52
Previous Close	43.16
Day's Range	39.79 - 44.52
52-Week Range	37.02 - 60.37
Beta	undefined

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 31, 2014

Employees 1,276

Stock Exchange NASDAQ

Ticker Symbol RARE

Website https://www.ultragenyx.com

Analyst Forecast

According to 14 analyst ratings, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $84.5, which is an increase of 110.67% from the latest price.

Buy 92.86%

Hold 7.14%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ultragenyx Pharmaceutical Inc. is scheduled to release its earnings on Feb 13, 2025, during market hours.
Analysts project revenue of $144.99M, reflecting a 13.81% YoY growth and earnings per share of -1.35, making a -11.18% decrease YoY.

Why Price Moved

5 months ago · Source

+14.31%

Ultragenyx Pharmaceuticals shares are trading high... Unlock content with Pro Subscription

5 months ago · Source

-1.93%

Ultragenyx Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.

News

1 week ago · zacks.com

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.

3 weeks ago · zacks.com

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.

2 months ago · seekingalpha.com

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Ultragenyx's strong Q3 earnings report, with a 42% YoY revenue increase, has reignited my interest in initiating a starter position in RARE. The company's promising pipeline, including late-stage prog...

2 months ago · zacks.com

Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates

RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.

2 months ago · seekingalpha.com

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO H...

2 months ago · zacks.com

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics co...

2 months ago · zacks.com

Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $2.23 per share a year ago.